AFP DEPARTMENT COLLECTION
This department includes information about new drugs from the perspective of the five attributes to be considered when weighing the advantages of one drug over another: Safety, Tolerability, Effectiveness, Price, and Simplicity.
Jan 15, 2020 Issue
Revefenacin (Yupelri) for the Treatment of Chronic Obstructive Pulmonary Disease
Revefenacin is a once-daily nebulized alternative to metered dose long-acting muscarinic antagonists for patients with moderate to severe COPD. Given its expense, complicated administration process, and lack of evidence that it improves key patient-oriented outcomes, its use should be limited to patients who are unable to use a metered dose inhaler.
Dec 15, 2019 Issue
Baloxavir Marboxil (Xofluza) for Influenza
Single-dose baloxavir should be limited to ill patients who cannot tolerate or comply with a course of oseltamivir. For otherwise healthy adults with confirmed influenza or influenza-like illness, the high cost of baloxavir may not justify the one-day reduction in symptoms of a self-limited illness.
Nov 15, 2019 Issue
Hydrogen Peroxide 40% (Eskata) for Seborrheic Keratosis
Hydrogen peroxide 40% topical solution is not particularly effective for removing seborrheic keratosis lesions, and skin reactions are common.
Oct 15, 2019 Issue
Elagolix (Orilissa) for Endometriosis Pain
Elagolix can decrease pain in women with endometriosis, but it is expensive and has adverse effects similar to those of other medications that decrease estrogen levels.
Sep 15, 2019 Issue
Glycopyrronium (Qbrexza) Topical Wipes for Hyperhidrosis
Glycopyrronium wipes are a useful alternative for the topical treatment of hyperhidrosis of the axillae in patients nine years and older who do not respond to or tolerate nonprescription antiperspirants or topical aluminum chloride.
Aug 15, 2019 Issue
Secnidazole (Solosec) for Bacterial Vaginosis
Secnidazole is much more expensive than generic metronidazole and other available treatments. However, it is a safe option for women who desire a single-dose treatment or for patients in whom treatment compliance is a concern.
Jul 15, 2019 Issue
Semaglutide (Ozempic) for Type 2 Diabetes Mellitus
Semaglutide can be added to existing treatment to improve glycemic control and induce weight loss. It may also protect against cardiovascular outcomes in patients with type 2 diabetes and established cardiovascular disease.
Jun 15, 2019 Issue
Erenumab (Aimovig) for Migraine Prophylaxis in Adults
Erenumab is a safe option for migraine prophylaxis in adults. However, it is expensive and should be reserved for patients who have experienced intolerable adverse effects while taking oral migraine prophylaxis medication or who have poor adherence to daily preventive treatment.
May 15, 2019 Issue
Glycopyrrolate (Lonhala Magnair) for Treatment of Chronic Obstructive Pulmonary Disease
Glycopyrrolate is a safe alternative to long-acting muscarinic antagonists delivered by metered-dose inhaler for patients with moderate to severe COPD.
Mar 15, 2019 Issue
Lofexidine (Lucemyra) for Treatment of Opioid Withdrawal Symptoms
Lofexidine has been shown to be as effective as clonidine at controlling some of the symptoms of withdrawal from opioid use. It may have a small additional benefit for maintaining abstinence in patients switched to buprenorphine or methadone for long-term maintenance.